Silence Therapeutics Posts First Human Data For Cardiovascular Candidate

Loading...
Loading...

Silence Therapeutics plc SLN showed that its RNAi technology could reduce a patient's lp(a) levels by 98% at a high dose.

  • Data comes from its phase 1 single ascending dose study of SLN360, an siRNA targeting lipoprotein(a) (Lp(a)), in healthy adults with high Lp(a).
  • High Lp(a), defined as ≥ 50 mg/dL (c.125nmol/L), affects approximately 20% of the world's population and is a genetic risk factor for cardiovascular disease.
  • SLN360 is a siRNA designed to lower Lp(a) production by targeting messenger RNA transcribed from the LPA gene.
  • Notably, the patients remained down 81% after 150 days, suggesting a treatment could be given just 2 to 4 times per year. 
  • Silence anticipates data from the extended follow-up period in Q3 of 2022.
  • Patient enrollment continues in the multiple ascending dose portion of the SLN360 phase 1 study. Silence remains on track to initiate the SLN360 phase 2 atherosclerotic cardiovascular disease study in 2H of 2022, pending regulatory discussions.
  • Price Action: SLN shares are trading 7.55% higher at $22.86 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...